MedTrace Logo

Imiquimod Treatment of Residual or Recurrent CIN Lesions: a Study Protocol

NCT02669459 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 433

Last updated 2018-02-06

No results posted yet for this study

Summary

The purpose of this study is to investigate if imiquimod can be used as a non-invasive option in the treatment of residual/recurrent CIN lesions.

Conditions

  • Cervical Intraepithelial Neoplasia

Interventions

DRUG

Imiquimod

12,5 mg imiquimod three times per week during 16 weeks

PROCEDURE

LLETZ

surgical treatment for CIN, current gold standard

Sponsors & Collaborators

  • Maastricht University Medical Center

    collaborator OTHER

  • Meander Medisch Centrum

    collaborator OTHER

  • Albert Schweitzer Hospital

    collaborator OTHER

  • Sint Franciscus Gasthuis

    collaborator OTHER

  • Catharina Ziekenhuis Eindhoven

    collaborator OTHER

  • Erasmus Medical Center

    lead OTHER

Principal Investigators

  • Heleen van beekhuizen, MD · Erasmus Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-05-31
Primary Completion
2019-03-31
Completion
2020-03-31

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02669459 on ClinicalTrials.gov